爱威科技股份有限公司2025年度业绩快报公告

Core Viewpoint - The company reported a preliminary financial performance for the year 2025, showing significant growth in revenue and net profit, driven by strong sales of specific products and effective cost management [2][3]. Financial Data and Indicators - The company achieved an operating revenue of 230.03 million yuan, representing a year-on-year increase of 13.14% [2]. - The net profit attributable to the parent company was 28.94 million yuan, up 26.72% year-on-year [2]. - The net profit attributable to the parent company after deducting non-recurring gains and losses was 23.07 million yuan, reflecting a substantial increase of 47.91% [2]. - Total assets at the end of the reporting period were 580.15 million yuan, a growth of 3.41% compared to the beginning of the period [2]. - The equity attributable to the parent company was 514.43 million yuan, increasing by 3.75% from the start of the period [2]. Operational Performance and Financial Condition - The revenue growth was primarily driven by strong sales of the reproductive tract secretion analysis instruments and related reagents, as well as the blood analysis production line launched in 2024 [2]. - The higher growth rate of net profit compared to revenue is attributed to effective cost control measures implemented since November 2024, which kept the growth of operating expenses below that of revenue [2]. - The company also undertook various cost-reduction and efficiency-enhancing measures across R&D, procurement, and manufacturing, leading to a decrease in the cost of main products [2].